These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1748141)

  • 61. Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man.
    Kramer WG; Kolibash AJ; Lewis RP; Bathala MS; Visconti JA; Reuning RH
    J Pharmacokinet Biopharm; 1979 Feb; 7(1):47-61. PubMed ID: 458556
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetic study of the digoxin-acenocoumarol interaction in rabbits.
    Martin-Suarez A; Atencio DR; Lopez FG; Santos M; Zarzuelo A; Mendez ME; Alberca I; Lanao JM
    Biol Pharm Bull; 2003 Jun; 26(6):813-7. PubMed ID: 12808292
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Some pharmacokinetic and pharmacodynamic interactions between digoxin and gentamicin.
    Staneva-Stoytcheva D; Kristeva E; Prodanova K
    Eur J Drug Metab Pharmacokinet; 1992; 17(1):1-8. PubMed ID: 1323465
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology.
    Antman EM; Arnold JM; Friedman PL; Smith TW
    Cardiovasc Drugs Ther; 1987 Aug; 1(2):183-9. PubMed ID: 3154322
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Extension of the serum digoxin concentration--response relationship to patient management.
    Kolibash AJ; Lewis RP; Bourne DW; Kramer WG; Reuning RH
    J Clin Pharmacol; 1989 Apr; 29(4):300-6. PubMed ID: 2723118
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pharmacodynamic modeling of digoxin-induced bradycardia.
    Vetticaden SJ; Barr WH; Allison TB
    J Pharmacokinet Biopharm; 1989 Feb; 17(1):89-107. PubMed ID: 2715933
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The rational pharmacology of digoxin.
    Heerdt PM; Heerdt ME
    J Clin Anesth; 1992; 4(5):419-35. PubMed ID: 1389200
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Danaparoid: a review of its use in thromboembolic and coagulation disorders.
    Ibbotson T; Perry CM
    Drugs; 2002; 62(15):2283-314. PubMed ID: 12381232
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.
    Wilde MI; Markham A
    Drugs; 1997 Dec; 54(6):903-24. PubMed ID: 9421696
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Breimer DD
    J Clin Pharmacol; 1991 Jul; 31(7):611-7. PubMed ID: 1716644
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172.
    De Boer A; Stiekema JC; Danhof M; Breimer DD
    Br J Clin Pharmacol; 1991 Jul; 32(1):23-9. PubMed ID: 1716140
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers.
    de Boer A; Stiekema JC; Danhof M; van Dinther TG; Boeijinga JK; Cohen AF; Breimer DD
    Antimicrob Agents Chemother; 1991 Oct; 35(10):2110-5. PubMed ID: 1759835
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pharmacokinetic considerations on Orgaran (Org 10172) therapy.
    Danhof M; de Boer A; Magnani HN; Stiekema JC
    Haemostasis; 1992; 22(2):73-84. PubMed ID: 1379967
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers.
    de Boer A; Stiekema JC; Danhof M; Moolenaar AJ; Breimer DD
    Eur J Clin Pharmacol; 1991; 41(3):245-50. PubMed ID: 1748141
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Orgaran (Org 10172) or heparin for preventing venous thrombosis after elective surgery for malignant disease? A double-blind, randomised, multicentre comparison. ANZ-Organon Investigators' Group.
    Gallus A; Cade J; Ockelford P; Hepburn S; Maas M; Magnani H; Bucknall T; Stevens J; Porteous F
    Thromb Haemost; 1993 Oct; 70(4):562-7. PubMed ID: 7509509
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases.
    Smith TW; Butler VP; Haber E; Fozzard H; Marcus FI; Bremner WF; Schulman IC; Phillips A
    N Engl J Med; 1982 Nov; 307(22):1357-62. PubMed ID: 6752715
    [TBL] [Abstract][Full Text] [Related]  

  • 77. ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.
    Francis RJ
    Comput Programs Biomed; 1984; 18(1-2):43-9. PubMed ID: 6547655
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.
    Ofosu FA; Modi GJ; Smith LM; Cerskus AL; Hirsh J; Blajchman MA
    Blood; 1984 Sep; 64(3):742-7. PubMed ID: 6235872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A novel anti-thrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity: a survey of its pharmacological properties in experimental animal models.
    Meuleman DG; Hobbelen PM; van Dedem G; Moelker HC
    Thromb Res; 1982 Aug; 27(3):353-63. PubMed ID: 6182627
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.